Target
Thymidylate Synthase (TS)
15 abstracts
Abstract
Adjuvant chemotherapy in clinical local advanced CRC following preoperational therapies and pT0-3N0M0 diagnosis (CANWATCH).Org: Kunming, China,
Abstract
Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.Org: Chonnam National University Medical School, Hwasun, South Korea, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile, National Cheng Kung University, Tainan, Taiwan, CHU Brest–Institut de Cancerologie et d’Hematologie ARPEGO Network, Brest, France,
Abstract
Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.Org: The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, Trinity Health IHA Medical Group,
Abstract
Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): A single-center, single-arm, exploratory clinical trial.Org: The Affifiliated Hospital of Qingdao University,
Abstract
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).Org: Memorial Sloan Kettering Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, Department of Radiology, Department of Colorectal Oncology,
Abstract
Size-related heterogeneity of colorectal liver metastases (CRLM) in patients with advanced RAS wild-type metastatic colorectal cancer (mCRC) treated in the PanaMa trial: Implication for treatment decisions.Org: Department of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, Charité– Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt- Universität Zu Berlin, Berlin, Germany, Charité– Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet Zu Berlin, Berlin, Germany, Klinikum Neuperlach/ Klinikum Harlaching, Department of Hematology, Oncology, and Palliative Care, Munich, Germany, Klinik Dr. Hancken GmbH, Department of Hematology, Oncology, and Palliative Care, Stade, Germany, Kliniken Maria Hilf GmbH, Moenchen-Gladbach, Germany, Oncological Practice UnterEms, Leer, Germany, University Medical Center Goettingen, Department of Gastroenterology, Gastrointestinal Oncology, and Endocrinology, Goettingen, Ge...,
Abstract
Capped F10, a novel DNA directed fluoropyrimidine, in TP53 mutated acute myeloid leukemia (AML).Org: Comprehensive Cancer Center of Atrium Health Wake Forest Baptist,
Abstract
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,
Abstract
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.Org: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan, National Cancer Center Hospital East, Japan, Kashiwa-Shi, Japan, Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan,
Abstract
Real-world treatment trends and outcomes in elderly patients with metastatic colorectal cancer in the United States.Org: Cleveland Clinic Taussig Cancer Instititute, Huntsman Cancer Institute, University of Utah,
Abstract
CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.Org: Juntendo University School of Medicine, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Hiroshima University, National Cancer Center Hospital Japan East, Kashiwa, Japan, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial.Org: Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France, Institut Gustave Roussy, Villejuif, France, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain,
Abstract
Survival outcomes with observation or adjuvant therapy in elderly patients with biliary tract cancer.Org: Emory University School of Medicine, Winship Cancer Institute, Emory University School of Medicine, Winship Cancer Center of Emory University, Winship Cancer Institute of Emory University, Winship Cancer Institute, Division of Surgical Oncology, Department of Surgery, Emory University,
Abstract
Management of tumor treating fields (TTFields) therapy-related skin adverse events in pleural mesothelioma: A single center experience of TTFields therapy concomitant with chemotherapy.Org: Mesothelioma Unit, SS Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy, Alessandria, Italy, Oncology Unit S. Chiara Hospital, Trento, Italy,
Abstract
Oral capecitabine or tegafur/gimeracil/oteracil as induction and adjuvant/maintenance chemotherapy in the management of stage III-IVb nasopharyngeal carcinoma: A systematic-review and meta-analysis.Org: University of Santo Tomas, Manila, Philippines, Trinity College Dublin, Dublin, Ireland, Autonomous University of Baja California, Mexicali, Mexico, Einstein Medical Center, Philadelphia, PA, Bridgeport Hospital, Bridgeport, CT,